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Insulin pumps:
Beyond basal-bolus
ABSTRACT
Insulin pumps are a major advance in diabetes management, making insulin dosing easier and more accurate
and providing great ﬂexibility, safety, and efﬁcacy for
people who need basal-bolus insulin therapy. They are
the preferred treatment for people with type 1 diabetes
and many with type 2 diabetes who require insulin. This
article reviews the basics of how insulin pumps work,
who beneﬁts from a pump, and how to manage inpatients and outpatients on insulin pumps.

KEY POINTS
Insulin pumps allow for more accurate insulin dosing
than multiple daily injections, resulting in less drastic
extremes in blood sugar.
Insulin pumps allow for more individualized basal insulin
coverage than long-acting injectable insulin.
Both the patient and provider need a good understanding
of insulin pump therapy for successful pump management.

*Dr. Shubrook has disclosed consulting and research for AstraZeneca, Eli Lilly, Novo Nordisk, and
Sanoﬁ.
doi:10.3949/ccjm.82a.14127

he advent of the insulin pump in the
late 1970s was a step forward in diabetes
T
treatment, and recent improvements make
1

these devices easier to use in intensive insulin management. Today, more than 400,000
people in the United States are thought to be
using an insulin pump.2
See related editorial page 843

With a pump, patients can adjust the dosage and discreetly give themselves boluses
by simply pushing a button instead of giving
themselves multiple daily injections. Also,
pump therapy can be tailored to correct for
hepatic glucose production in a way that injections cannot.
This article reviews the clinical application
of continuous subcutaneous insulin therapy—
ie, the insulin pump—and provides recommendations for patient selection and management.
■ INDICATIONS FOR AN INSULIN PUMP
The American Association of Clinical Endocrinologists3 recommends considering an insulin pump for patients with type 1 or 2 diabetes
mellitus who have a clear indication:
• Suboptimal control on basal-bolus injections, ie, not achieving glycemic goals despite maximal adherence to multiple daily
injections
• Wide and erratic glycemic excursions
• Frequent severe hypoglycemia, or hypoglycemia unawareness
• A marked “dawn phenomenon” (spike in
blood glucose level early in the morning)
• Pregnancy or planning for pregnancy
• Erratic lifestyle
• Personal preference.

CL EVEL AND CL I NI C J O URNAL O F M E DI CI NE

V O L UM E 82 • NUM BE R 12

DE CE M BE R 2015

835

INSULIN PUMPS

TABLE 1

Who is a good candidate for an insulin pump?
Patients with type 1 diabetes who:
Self-monitor blood glucose four times per day
Take injections more than three times a day
Have completed diabetes education and carbohydrate-counting training
Have evidence of autoimmunity (positive for islet-cell antibodies
or glutamic acid decarboxylase antibodies)
Have low C-peptide with normal to high glucose levels
Patients with gestational diabetes who:
Self-monitor blood glucose and are on multiple daily injections
Patients with type 2 diabetes who:
Meet the same multiple-daily injection and self-monitoring requirements
as for type 1 diabetes
Have evidence of beta-cell failure with low C-peptide

■ WHO IS A GOOD CANDIDATE
FOR AN INSULIN PUMP?
Good candidates for a pump are patients with
type 1 diabetes (and some with type 2) who are
well versed in taking multiple daily injections,
are already checking their glucose four or more
times daily, “counting carbs” (estimating or,
preferably, measuring how much carbohydrate
they are eating, and limiting their intake acA pump
cordingly), and demonstrate the ability to adis not a shortcut just their dosing appropriately (Table 1).
A pump is not a shortcut to checking gluto checking
cose less frequently or making fewer decisions.
glucose less
However, for those who actively manage their
diabetes, it provides more real-time flexibility
frequently,
and some important safety features, as disor to making
cussed below.

fewer decisions

■ IS A PUMP BETTER THAN INJECTIONS?
Several studies have compared insulin pump
therapy and multiple daily injections.4–7 While
some found no difference in glucose control
in terms of hemoglobin A1c or hypoglycemia,
others showed improved glucose control with
pumps in patients who had higher baseline
hemoglobin A1c levels (> 10%).6 In this subgroup, a pump lowered hemoglobin A1c an
additional estimated 0.65% compared with
multiple daily injections.6 Fructosamine levels
also improved in pump users.6
Using continuous glucose monitoring
for 3 days in a study in children with type 1
diabetes, Schreiver et al8 found lower insulin
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requirements and less-severe glycemic excursions with a pump than with multiple daily
injections.
A 2013 study9 of 57 patients ages 13 to 71
with type 2 diabetes who were struggling to
control their blood sugar with multiple daily
injections found that they achieved better
control with less insulin using a pump.
A meta-analysis found pump therapy to be
more effective than multiple daily injections
for those who used it more than 1 year.10
■ ADVANTAGES AND DISADVANTAGES
OF INSULIN PUMP THERAPY
Intensive glucose control reduces microvascular complications in type 1 diabetes.11–14
The advantages of using a pump include better adherence, more accurate dosing, greater
lifestyle flexibility, control of the dawn phenomenon without induction of nocturnal hypoglycemia, and the ability to suspend or temporarily reduce basal insulin to compensate for
increased physical activity.15
Disadvantages include the high degree of
technical aptitude required, the need for highlevel engagement, skin reactions to tape, a
higher risk of diabetic ketoacidosis from pump
malfunction, infusion-site problems such as
“tunneling” of insulin (leakage of insulin
along the outside of the cannula and back to
the skin surface) and clogging of the infusion
set, and a risk of inactivation of insulin from
exposure to heat, which can lead to ketoacidosis in a few hours if not addressed promptly.15
■ IS IT COST-EFFECTIVE?
There is evidence that continuous subcutaneous insulin infusion is cost-effective, both in
general and compared with multiple daily injections for children and adults with type 1 diabetes mellitus. Cohen and Shaw16 found that
life expectancy and quality-adjusted life-years
increased in pump users, although the price
per life-year gained varied greatly depending
on the model used.
And this therapy is expensive. Most pumps
cost more than $6,000, and supplies cost about
$300 per month. Most insurance providers
cover this therapy for patients with type 1 diabetes (Table 2) but less often for those with
type 2. Further, many insurance policies have
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copayments, and patients may find a 20% copayment a significant financial burden. Physicians need to obtain preapproval for insulin
pumps from the insurance company. Typically,
prescriptions for supplies are written annually.
Despite these significant costs, most patients
with type 1 diabetes who use an insulin pump
find that the benefits of improved control and
greater independence justify the cost.
An annual review of currently available
insulin pumps and other diabetes-related
equipment is published in Diabetes Forecast.17

TABLE 2

Centers for Medicare and Medicaid Services
reimbursement requirements for insulin pumps
The patient has completed a comprehensive diabetes education
program and has been receiving multiple daily injections of insulin
with frequent self-adjustments for at least 6 months before pump
initiation.
The patient has documented self-monitoring of blood glucose
frequency an average of at least four times per day during the
previous 2 months.
The patient must also meet at least one of the following criteria:

■ PATIENT PERSPECTIVE
ON INSULIN PUMP USE

• Hemoglobin A1c > 7.0%

Many patients who use a pump find that it
gives them greater flexibility to adjust to dayto-day changes in schedules and routines.
For example, consuming an extra serving at
a meal could necessitate another injection
for a patient on multiple daily injections, but
a pump user would need only to push a few
buttons. With cell phone apps available to
control some pumps, many people find that
an insulin pump is more discreet and easier
to manage than carrying around injection
supplies. Further, the complex calculations of
carbohydrate ratios and correction factors are
easier and more accurate with a pump.
In an open-label randomized study,18 29 of
41 patients with type 1 diabetes said they preferred a pump to multiple daily injections.
Conversely, some people do not want a
pump because it is attached all the time and
identifies them to others as having an illness.
Other patients do not trust a machine and
want control in their own hands. (Actually,
machines typically are much more reliable
and less mistake-prone than humans.)
■ HOW DOES A PUMP WORK COMPARED
WITH MULTIPLE DAILY INJECTIONS?
Patients taking multiple daily injections must
use two types of insulin: a long-acting one
that reaches a steady level in the blood without a peak and lasts from 12 to 24 hours, and
a rapid-acting one taken with meals, usually
having a peak of action and an effect lasting 3 to 5 hours. The idea is to approximate
normal insulin patterns, with a basal level in
the background and peaks (boluses) of insulin

• History of recurrent hypoglycemia
• Wide ﬂuctuations in blood glucose before mealtime
• Dawn phenomenon with fasting plasma glucose frequently
> 200 mg/dL, or a history of severe glycemic excursions
• Patient on pump therapy before enrollment and has documented
self-monitoring of blood glucose an average of at least four times
per day during the month before enrollment.
• Fasting C-peptide ≤ 110% of the lower limit of normal or ≤ 200%
of the lower limit of normal if creatinine clearance is ≤ 50 mL/min
with concurrent fasting plasma glucose ≤ 225 mg/dL
• Beta-cell autoantibody-positive (islet-cell antibodies or glutamic acid
decarboxylase antibodies)
Centers for Medicare & Medicaid Services. https://www.cms.gov/manuals/iom/list.asp.

with carbohydrate intake.
Insulin pumps use only one kind of insulin—
a rapid-acting one, ie, lispro, aspart, or glulisine.
They preserve the basal-bolus concept, but with
many refinements (discussed below).15
Most pumps are attached to the patient by
plastic tubing that connects the reservoir to
a subcutaneous cannula or steel needle. However, some pumps have a reservoir directly attached to a subcutaneous cannula without the
tubing. This type of pump is controlled with a
remote device.
The infusion set (cannula or needle and
tubing) and the site should be changed every
third day to minimize the risk of infection and
abnormal delivery due to protein buildup on
the cannula os, epithelial healing, and irritation around the site. Failure to do so often results in higher blood glucose concentrations.19
The patient and healthcare team work to-
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gether to calculate the patient’s daily insulin
needs, and the pump is programmed based on
the patient’s requirements, lifestyle, and sensitivity to insulin. Once the pump is started, the
patient operates it to deliver the insulin dose
according to carbohydrate intake and blood
glucose level.
■ PUMP SETTINGS
Basal rate
The basal rate is programmed by the physician
and is intended to mimic physiologic insulin
release. The pump can be set to a number of
basal rates within any 24-hour period. This
provides more physiologic matching of insulin
delivery to hourly insulin needs based on the
patient’s daily schedule.
If the patient has been taking multiple
daily injections, the hourly basal rate can be
calculated by dividing the daily basal dose by
24. However, lower rates are usually used after
midnight, and rates are increased early in the
morning to counteract the dawn phenomenon.
The rates can also be adjusted temporarily (for up to 24 hours), with a feature called
the temporary basal rate. People tend to have
higher blood glucose levels when they have a
Most insulin
respiratory illness, are under significant stress,
pumps cost
or are menstruating. Thus, a person with influenza could increase the basal rate by 25%, or
more than
a student could run a temporary basal rate of
$6,000,
150% for 4 hours before taking a final exam.
Conversely, exercising increases insulin’s
plus about
effectiveness at the muscle level, and insulin
$300 per month requirements drop. To counteract this, one
would temporarily decrease the basal rate in
for supplies
the pump before exercising.
Many factors affect the bolus dose
A bolus of insulin is given for meals and to
correct hyperglycemia, as with multiple daily
injections. A pump calculates the bolus based
on the carbohydrate ratio, correction factor,
or both. These ratios are programmed into the
pump by the physician. A benefit of the insulin pump is that the patient just has to input
the amount of carbohydrates to be eaten or record a blood glucose level and the pump will
calculate the bolus dose of insulin to be given.
The carbohydrate ratio is the amount of
insulin that should be taken per amount of
carbohydrate. A typical ratio is 1:15, meaning
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that the patient should take 1 unit of insulin
for every 15 g of carbohydrates to be eaten.
This varies by patient depending on insulin
sensitivity.
The correction factor describes how much
the glucose level is expected to drop per unit
of insulin given. For example, if the target
glucose level is 100 mg/dL and the correction
factor is 25, then the patient will get 1 unit of
correction of insulin if his or her glucose level
is 125 mg/dL, 2 units if it is 150 mg/dL, and so
on. A pump can dispense fractions of a unit.
The target glucose level or range is set by
the physician and patient and is one of the
factors the pump uses in calculating a bolus
dose. Insulin pumps allow for multiple target
glucose levels. Commonly, to minimize the
risk of hypoglycemia, a higher (less strict) target is set for bedtime and overnight than for
daytime.
Active insulin time defines how soon the
patient can take another bolus.
Often, people eat more than they thought
they would. They may also find that the glucose level did not increase or decrease as much
as expected. Many patients who actively manage their glucose take additional boluses of
insulin after a meal if their glucose is higher
than they thought it would be. A patient
taking injections cannot know how much of
the insulin from the before-meal bolus is still
working and has to guess.
Insulin pumps use a logarithmic formula
to calculate this and prevent the user from
“stacking” insulin boluses and lowering the
glucose level too much. For example, if the
active insulin time is 4 hours and the patient
took a bolus for lunch at noon, he or she would
be unable to take a full insulin correction dose
until 4:00 pm. The patient can override this
feature. Although the active insulin time varies from patient to patient, it is rarely more
than 4 hours.
Additional safety features
Suspend. When a person who is taking insulin
injections starts to experience hypoglycemia,
he or she has one option—to eat something
to treat the low blood glucose. The insulin
injection has already been taken and cannot
be reversed. However, with an insulin pump
the patient can first suspend the pump so that
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no additional insulin is infused until it is safe
again, and then eat to treat the low sugar level. This allows the patient to eat less, prevent
overtreating, and, hopefully, prevent rebound
hyperglycemia.
Reverse correction. When patients take
insulin for an upcoming meal, they estimate
the amount needed for the carbohydrates that
they are about to eat as well as how much
correction is needed. If their glucose level is
below the target range, they may or may not
subtract insulin from the dose to achieve the
glucose target. The pump does this automatically, resulting in a lower dose of insulin for
that bolus. This allows the patient to take a
bolus for a meal even if he or she is below the
target, and thus prevent hyperglycemia.
■ CAN INSULIN PUMPS BE USED
IN THE HOSPITAL?
Patients can keep using their insulin pump in
the hospital under the right conditions.
Inpatient hypoglycemia increases the
risk of death, and although not all patients
require tight glycemic control, there is still
benefit in avoiding extremes in blood sugar
levels,20 including at night.20–22 Insulin pump
therapy, when used in the hospital, results in
fewer episodes of severe hyperglycemia (glucose levels > 300 mg/dL) and hypoglycemia
(levels < 40 mg/dL) than multiple daily injections.22 Moreover, most pump users feel more
comfortable when they can manage their own
therapy. Using the pump in the hospital has
the additional benefit that patients can treat
themselves before and after meals easily with
less staff time and effort.
Bailon et al23 retrospectively studied 35
patients with insulin pumps in 50 hospitalizations. More than half of the patients were
allowed to continue using their pump in the
hospital. Reasons for discontinuing the pump
included lack of access to supplies, unfamiliarity with the pump, attempted suicide, malfunctioning hardware, diabetic ketoacidosis,
and altered mental status. Patients using their
pump had fewer episodes of hypoglycemia
(glucose levels < 70 mg/dL) than patients who
removed their pump. In patients who continued using the pump throughout their hospitalization, no adverse events (eg, site infection or

mechanical failure) were noted.
Leonhardi et al24 reviewed 25 hospital admissions, and the outcomes were similar to
those reported by Bailon et al,23 with no adverse outcomes related to the pumps.
When using an insulin pump in the hospital
When a physician wants a patient to continue
using an insulin pump in the hospital, a number of things must happen. The nursing staff
must be informed that the patient is wearing
a pump and can self-administer insulin. Most
facilities will still follow routine protocols for
checking blood glucose but will document
that the patient is administering his or her
own insulin. The patient must be well enough
to manage the pump. If the infusion site needs
to be changed, the patient would be expected
to do so with his or her own supplies.
Imaging and insulin pumps
Advice differs on what to do if a patient with
an insulin pump needs to undergo radiographic imaging. For example, the University
of Wisconsin radiology department says it is
safe to keep an insulin pump in place if the
x-ray beam will be on for less than 3 seconds
at a time and if the device is covered by a lead
apron.25 However, radiation can induce electrical currents in the circuitry, which can alter the function of the pump. For this reason,
some manufacturers recommend removing
the device before the patient enters any room
in which radiation or magnetic resonance imaging will be used.26–31

Insulin pumps
preserve
the basal-bolus
concept,
but with
refinements

Insulin pumps and surgery
Insulin pumps have been used in the perioperative and intraoperative periods, with positive outcomes.32 An analysis of 20 patients on
pumps undergoing a total of 23 surgeries (mostly orthopedic procedures) found that 13 of the
20 patients wore their pump during surgery. No
adverse events were noted in any of these cases,
although the sample size was small.33
Corney et al34 retrospectively compared
insulin pumps with alternative methods of
perioperative glucose management. Multiple
surgical specialties were included. No significant difference in mean blood glucose levels was found between those who continued
to use their pump and those who used other
methods. In those who continued to use their
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pump, there were no episodes of intraoperative technical difficulties related to the pump.
Any patient who may be undergoing a procedure or surgery must let the surgeon and anesthesiologist know that he or she has a pump. If
the infusion site is too close to the site of the
surgery or procedure, it must be moved.
Concerns during surgery include catheter
or site disconnection or loss, crystallization
within the tubing (a potential problem not
limited to surgery), and pump malfunction.
If the procedure involves imaging, the pump
should probably be disconnected or covered by
lead shielding as directed in the pump manufacturer’s manual. The surgeon and anesthesiologist must decide whether to continue use of
a pump during a surgical procedure. However,
the study by Corney et al34 shows it is possible.
Most office-based procedures can be done
with the insulin pump in place, as the patient
is not under general anesthesia and so can adjust the insulin regimen as needed.
Abdelmalak et al,35 in a comprehensive
review of insulin pump use in noncardiac surgery, commented that the type of surgery may
play a role in determining the best approach
to perioperative glucose management. Major
The infusion
surgery causes a large inflammatory response
set and the site that makes it difficult to control blood sugar,
especially when steroids or beta agonists are
should be
given, whereas minor surgery does not affect
blood glucose nearly as much. The authors ofchanged
fered recommendations on pump use during
every 3 days
various surgical procedures depending on the
length of the procedure:
• If surgery is anticipated to last less than 1
hour, then keep the insulin pump on, and
have the patient manage corrections preoperatively and postoperatively.
• For surgery of intermediate length (1–3
hours), have the patient take a bolus of 1
hour’s worth of insulin (based on the basal
rate for that time period) before the procedure, then remove the insulin pump. Do
this only if blood sugar is normal or close
to normal. If the patient is severely hyperglycemic, remove the insulin pump and
start an intravenous insulin infusion.
• If the procedure will take more than 3
hours, remove the pump and start an insulin infusion regardless of the blood sugar
level.35
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■ AIR TRAVEL AND INSULIN PUMPS
Insulin pumps can be easy to manage during
airline travel if the user is prepared (Table 3).
First, it is important to have a letter from
the treating physician stating that the pump
is a necessary medical device. All supplies
should be carried on and in a separate bag for
easy inspection. The more forthcoming the
user is at the security checkpoint, the easier
the process.
According to the Transportation Security
Administration, insulin pump users can keep
their pump on during screening, and the metal
detectors and full-body scanners will not harm
the device.36
However, manufacturer recommendations
differ. Medtronic recommends that patients
not expose their insulin pump to x-rays, and
that instead of going through a full-body scanner the patient should request a pat-down.37
Animas recommends the same.38 OmniPod
states that their system can be worn through
airport imaging, making it the only approved
continuous insulin delivery system that can be
taken through airport imaging.39
Another potential problem is the change
in atmospheric pressure during takeoff and
landing. Bubbles can form in the insulin reservoir as air pressure decreases with ascent,
thereby displacing insulin from the pump to
the patient. The opposite happens during descent. King et al40 corroborated this phenomenon with Animas and Medtronic pumps.
Asante recommends removing their pump
tubing during takeoff and landing.30
■ IF PROBLEMS ARISE
Like any machine, an insulin pump can fail.
Most failures result in lack of insulin delivery—
the patient does not get excess insulin from
insulin pump failure. Excess insulin delivery
is most often due to operator error. All insulin
is either preprogrammed (basal by provider or
patient) or must be confirmed by the patient
at the time of delivery (meal or correction boluses).
Pump manufacturers have 24-hour support
programs and hotlines, with experts who will either walk the patient through the problem or send
a replacement pump—often within 24 hours.
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■ EVOLVING TECHNOLOGY

TABLE 3

Pump technology is evolving quickly. On the
way are “smart” pumps that interact with other
systems, smaller pumps with advanced touchscreen features, and patch pumps that do not
have tubing but operate similarly to pumps
with tubing (ie, a cannula is still required for
insulin delivery).
Some insulin pumps can be linked to an
external glucose sensor. These systems provide
a great amount of information to the patient
and provider. Often, there is increased awareness of fluctuations in glucose, allowing earlier
intervention to prevent high and low glucose
excursions. Sensor-augmented pumps may
further improve safety by suspending infusion
during hypoglycemia.41,42
Researchers continue to strive for closedloop systems that would allow the pump to
automatically respond to circulating glucose
and thus provide truly physiologic control.43
A recent study showed the effectiveness of the
outpatient use of a bihormonal (insulin and
glucagon) “bionic pancreas,” which provided
■ REFERENCES

Recommendations for patients
with an insulin pump who plan air travel
• Bring a note from your physician stating you have diabetes mellitus
and are carrying insulin supplies.
• Always bring extra supplies (pump supplies, syringes, test strips,
lancets, and an extra insulin bottle). Once opened, a bottle of insulin
can be kept at room temperature for 28 to 42 days. Those that are
unopened should be refrigerated.
• Notify the Transportation Security Administration (TSA) staff that
you wear an insulin pump and have diabetic supplies before sending your belongings through the x-ray machine. If you carry a pump
with tubing, you can detach the device and send it through the x-ray
machine. TSA staff will swab your hands after you touch the pump to
test for explosive material, which is standard procedure.
• If you are concerned about insulin dosing during takeoff and landing, you can detach your pump at these times. Make sure to prime the
tubing again before reattaching it to ensure the tubing is free of air.
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